Caribou Biosciences Inc (NASDAQ:CRBU) has a beta value of 2.36 and has seen 0.55 million shares traded in the recent trading session. The CRBU stock price is -491.67% off its 52-week high price of $4.97 and 0.0% above the 52-week low of $0.84. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.02 million shares traded. The 3-month trading volume is 1.24 million shares.
The consensus among analysts is that Caribou Biosciences Inc (CRBU) is Buy stock at the moment, with a recommendation rating of 1.25. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 3 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.48.
Caribou Biosciences Inc (NASDAQ:CRBU) trade information
Sporting 0.43% in the green today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the CRBU stock price touched $0.84 or saw a rise of 16.83%. Year-to-date, Caribou Biosciences Inc shares have moved -46.87%, while the 5-day performance has seen it change -4.13%. Over the past 30 days, the shares of Caribou Biosciences Inc (NASDAQ:CRBU) have changed -23.21%. Short interest in the company has seen 8.82 million shares shorted with days to cover at 8.49.
Wall Street analysts have a consensus price target for the stock at $3, which means that the shares’ value could jump 72.0% from the levels at last check today. The projected low price target is $3.0 while the price target rests at a high of $3.0. In that case, then, we find that the latest price level in today’s session is -257.14% off the targeted high while a plunge would see the stock gain -257.14% from the levels at last check today.
Caribou Biosciences Inc (CRBU) estimates and forecasts
The company’s shares have lost -56.90% over the past 6 months. Revenue growth from the last financial year stood is estimated to be -14.19%.
5 analysts offering their estimates for the company have set an average revenue estimate of 1.44M for the current quarter. 5 have an estimated revenue figure of 1.48M for the next ending quarter. Year-ago sales stood 2.43M and 3.46M respectively for this quarter and the next, and analysts expect sales will shrink by -40.72% for the current quarter and -14.19% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -33.41% over the past 5 years. Earnings growth for 2025 is a modest -6.20% while over the next 5 years, the company’s earnings are expected to decrease by -4.17%.
CRBU Dividends
Caribou Biosciences Inc is expected to release its next earnings report on 2025-Mar-09 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Caribou Biosciences Inc (NASDAQ:CRBU)’s Major holders
Insiders own 10.08% of the company shares, while shares held by institutions stand at 61.64% with a share float percentage of 68.55%. Investors are also buoyed by the number of investors in a company, with Caribou Biosciences Inc having a total of 180.0 institutions that hold shares in the company. The top two institutional holders are BLACKROCK INC. with over 6.95 million shares worth more than $11.39 million. As of 2024-06-30, BLACKROCK INC. held 7.6907% of shares outstanding.
The other major institutional holder is VANGUARD GROUP INC, with the holding of over 4.54 million shares as of 2024-06-30. The firm’s total holdings are worth over $7.45 million and represent 5.0891% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF. As of Dec 31, 2024, the former fund manager holds about 2.91% shares in the company for having 2.7 shares of worth $2.25 million while later fund manager owns 2.17 shares of worth $1.81 million as of Feb 28, 2025, which makes it owner of about 2.34% of company’s outstanding stock.
